CD34+/CD133+ Expression

Clinical information

Diagnostic Utility:

Test that quantifies

• cells positive for the CD34 membrane receptor (surface antigen of hematopoietic stem cells)
• cells positive for the CD133 membrane receptor (found in hematopoietic stem cells and endothelial cells)

and determines cellular viability.

It is a determination used as a quality control of products from positive selections of CD133 cells for the treatment of diseases such as Asherman's Syndrome or by IPS cells.

Method: 

Flow cytometry

Reference Values

The results are quantitative. CD34 and CD133 concentrations can vary greatly depending on the type of sample/product.

Diagnostic Algorithm:

Not applicable.

Response Time:

1 day.

Specimen information

Sample: Peripheral blood, umbilical cord blood, bone marrow, apheresis. 
Tube: EDTA K3 tube (peripheral blood) or Additive-free tube (anticoagulated samples).
Minimum volume: 100 µL
 

Stability:

• At room temperature: 1 day
• In refrigeration: 1 day
• Cryopreserved between -156^oC and -196^oC: 20 years

Transport instructions: Room temperature

Reason for rejection: Sample with DNA or precipitates

Administrative information

BST Code: CEL017
Test Description: CD34+/CD133+ expression
Synonyms: CD133+
Section: Cellular Laboratory
BST Fee: Check the updated fees here.

Profiles: This test must always be requested together with test CEL007. It is also carried out within the following profiles:

References

• Cervelló et al. Human CD133+ bone marrow-derived stem cells promote endometrial proliferation in a murine model of Asherman syndrome; Fertility and Sterility, Volume 104, Issue 6, December 2015, Pages 1552-1560.e3.
• Santamaria X, et al. Autologous cell therapy with CD133+ bone marrow-derived stem cells for refractory Asherman’s syndrome and endometrial atrophy: a pilot cohort study; Human Reproduction, Vol.31, No.5 pp. 1087–1096, 2016.
• NCF Parte IV: Directrices sobre normas de correcta fabricación específicas para Medicamentos de Terapia Avanzada.